Mesoblast Limited (MESO) — Stock Score Summary

Mesoblast Limited (MESO) has a MoatMap StockRank of 25/100 based on Quality (28/100), Value (41/100), and Momentum (42/100) factor scores. The current signal is SELL. Mesoblast is a highly speculative biotech company with a history of cash burn and regulatory delays. It lacks the predictable owner earnings, high ROIC, and established commercial moats required for our concentrated portfolio.

Mesoblast Limited is a global leader in the development of allogeneic mesenchymal stromal cell (MSC) therapies for inflammatory and cardiovascular conditions, leveraging its proprietary platform technology. The company's competitive moat is built on its extensive intellectual property and expertise in scalable MSC manufacturing, positioning it at the forefront of regenerative medicine.

Key Financial Metrics

Price$14.28
Market Cap$1.9B
P/E (Forward)-213.29
Price/Book3.35
Return on Equity-18.2%
Return on Invested Capital-11.7%
Debt/Equity23.52
Gross Margin-35.5%
Operating Margin-55.2%
Revenue Growth1526.8%
Free Cash Flow$-69M

Mesoblast Limited operates in the Biotechnology industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Mesoblast Limited’s (MESO) StockRank?
MoatMap’s StockRank for Mesoblast Limited (MESO) is 25/100, with a Sell signal. It is a composite of Quality (28), Value (41), and Momentum (42) factor ranks across MoatMap’s 19,000+ stock universe.
Does Mesoblast Limited have an economic moat?
Mesoblast Limited (MESO) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Mesoblast Limited a buy, hold, or sell?
MoatMap’s current signal for Mesoblast Limited (MESO) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Mesoblast Limited in?
Mesoblast Limited (MESO) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).
Browse all ranked stocksMESO deep dive reportAI ChampionsHow we score stocksSense-check another stock